<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044379</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-026/ IPM 038</org_study_id>
    <nct_id>NCT03044379</nct_id>
  </id_info>
  <brief_title>Dapivirine Gel Rectal Safety and PK Study</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dapivirine Gel Rectal Safety and PK Study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double Blind, Placebo-Controlled Phase 1 Safety and Pharmacokinetic Study of
      Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Current program is on hold, not for safety reason
  </why_stopped>
  <start_date type="Actual">September 29, 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety To characterize the systemic and compartmental pharmacokinetics of dapivirine gel following rectal application.</measure>
    <time_frame>9-12 months</time_frame>
    <description>To evaluate the safety of dapivirine gel formulation when applied rectally.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>9-12 months</time_frame>
    <description>To identify product attributes considered likely to challenge and facilitate future sustained use of rectally applied dapivirine gel.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV 1 Infection</condition>
  <arm_group>
    <arm_group_label>Dapivirine Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to receive a single dose of dapivirine gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Gel HEC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive the universal HEC placebo gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine gel (0.05%)</intervention_name>
    <description>MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.</description>
    <arm_group_label>Dapivirine Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Universal HEC placebo gel</intervention_name>
    <arm_group_label>Placebo Gel HEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 - 45 years (inclusive), verified per site SOP

          -  Able and willing to provide written informed consent

          -  HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in Appendix
             II and willing to receive HIV test results

          -  Able and willing to provide adequate locator information, as defined in site SOP

          -  Available to return for all study visits and willing to comply with study
             participation requirements

          -  In general good health at Screening and Enrollment, as determined by the site IoR or
             designee

          -  Per participant report, a history of consensual RAI at least once in the past calendar
             year

          -  Willing to not take part in other research studies involving drugs, medical devices,
             genital products, or vaccines for the duration of study participation, including the
             time between Screening and Enrollment

        Exclusion Criteria: At Screening:

          -  Hemoglobin Grade 1 or higher*

          -  Platelet count Grade 1 or higher*

          -  White blood count Grade 2 or higher*

          -  Serum creatinine 1.3 the site laboratory upper limit of normal (ULN)

          -  International normalized ratio (INR) 1.5 the site laboratory ULN

          -  Aspartate aminotransferase (AST) or alanine transaminase (ALT) Grade 1 or higher*

          -  Positive for hepatitis C antibody

          -  Positive for hepatitis B surface antigen

          -  History of inflammatory bowel disease by participant report
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

